Outset Medical, Inc. has announced its financial results for the second quarter ending June 30, 2025. The medical technology company reported a net revenue of $31.4 million, marking a 15% increase from the same period last year. This growth was primarily driven by a 25% increase in Tablo console revenue. Additionally, recurring revenue from Tablo consumables and services rose by 11% to $22.5 million, propelled by a 17% increase in consumable revenue. The company reported a net loss of $18.5 million for the quarter, an improvement from the $34.5 million net loss recorded in the same quarter of 2024. On a non-GAAP basis, the net loss was $15 million compared to a non-GAAP net loss of $24.7 million for the same period in 2024. As of June 30, 2025, Outset Medical's total cash, including restricted cash, cash equivalents, and short-term investments, stood at $187.4 million. Looking ahead, Outset Medical has raised its 2025 revenue guidance to a range of $122 million to $126 million, up from the previous guidance of $115 million to $125 million. The company expects its non-GAAP gross margin for 2025 to remain in the high-30% range and anticipates using less than $50 million in cash for the year, a significant reduction from over $100 million used in 2024.